VEGFA and head and neck squamous cell carcinoma: An anti-VEGF vaccine (CIGB-247) was assessed in advanced solid in a Phase 1 clinical trial with promising results, as it was well tolerated, safe, and was shown to be immunogenic [176], but evaluation in HNSCC has not yet been undertaken.